Anthem Biosciences IPO: Investor Guide – Singhvi’s Forecast & Strategies

“`html

Anthem Biosciences Poised for Strong Debut on BSE,NSE

july 21,2025

By Archyde News Desk

Anthem Biosciences Ltd., a fully integrated biopharmaceutical company, is set to make its trading debut today, Monday, July 21, 2025, on both the Bombay Stock Exchange (BSE) and the National Stock exchange (NSE).

The company’s Initial Public Offering (IPO), which concluded its subscription period on July 16, was priced at Rs 570 per share.

Market expert Anil Singhvi forecasts a robust listing for Anthem Biosciences, anticipating shares to trade above the Rs 700 mark.

Singhvi, managing editor at Zee Business, projects the stock could possibly list in the Rs 715 to Rs 730 range.

Investment Outlook

For investors seeking immediate gains, Singhvi recommends applying for the IPO with an eye on listing day profits.

He also advises a long-term investment horizon, suggesting a holding period of two to three years for critically important returns.

Short-term traders are advised to maintain a position with a strict stop-loss set at Rs 675.

Singhvi emphasized that long-term investors should consider adding Anthem Biosciences to their portfolios.

Understanding Anthem biosciences

Anthem Biosciences Ltd. operates across the entire pharmaceutical value chain, from the initial stages of drug discovery and meticulous development to full-scale manufacturing.

This integrated approach allows the company to maintain control over quality and efficiency throughout its operations.

Frequently Asked Questions About Anthem Biosciences Listing

What is Anthem Biosciences Ltd.?

Anthem Biosciences Ltd. is a biopharmaceutical company engaged in drug discovery, development, and manufacturing.

When is Anthem biosciences listing on the stock market?

Anthem Biosciences is scheduled to list on the BSE and NSE on Monday, july 21, 2025.

What was the IPO price for Anthem Biosciences?

The IPO issue price for Anthem Biosciences was Rs 570 per share.

What is the listing gain expectation for Anthem Biosciences?

Market expert Anil Singhvi expects significant listing gains, with the stock potentially trading between Rs 715 and Rs 730.

What is the long-term investment advice for Anthem Biosciences shares?

The advice is to hold the stock for a long-term viewpoint of 2-3 years for potential substantial returns.

What is the recommended stop loss for short-term investors in Anthem Biosciences?

What are the potential implications of a failure in Anthem Biosciences’ phase 3 clinical trials for ANP709 on the IPO stock price?

Understanding Anthem Biosciences & the IPO Details

Anthem Biosciences, a clinical-stage biopharmaceutical company, is generating notable investor interest with its upcoming Initial Public Offering (IPO). Focused on developing innovative therapies for gastrointestinal (GI) diseases, the company’s lead candidate, ANP709, targets Short Bowel Syndrome (SBS). This investor guide breaks down the key aspects of the Anthem Biosciences IPO, incorporating insights from market analyst singhvi, and outlines potential strategies for investors.

Key IPO Details (as of July 21, 2025 – subject to change):

Ticker Symbol: ANTM (Proposed)

Exchange: NASDAQ (Expected)

Offering Price: $15 – $17 per share (Preliminary Range)

Shares Offered: 10 Million (Estimated)

Gross proceeds: $150 – $170 Million (Estimated)

Use of Proceeds: Primarily funding for Phase 3 clinical trials of ANP709, and general corporate purposes.

Underwriters: Leading investment banks including Jefferies and Piper Sandler.

Singhvi’s Forecast: A Bullish outlook on ANTM

Market analyst Singhvi, known for his accurate pre-IPO assessments, has expressed a cautiously optimistic outlook on Anthem Biosciences. His analysis highlights the significant unmet medical need in SBS, a debilitating condition affecting individuals with limited small intestine function.

Singhvi’s Key Points:

Strong Pipeline: ANP709 demonstrates promising results in Phase 2 trials, showing potential for substantial advancement in SBS patients.

Large Addressable Market: The SBS market is estimated at over $1 billion annually, offering significant revenue potential.

First-in-Class Potential: ANP709’s unique mechanism of action could position it as a first-in-class therapy, capturing a substantial market share.

Risk Factors: Singhvi cautions investors to be aware of the inherent risks associated with clinical-stage biopharmaceutical companies, including trial failures and regulatory hurdles. He recommends a diversified portfolio approach.

valuation: Singhvi suggests the IPO pricing reflects a reasonable valuation, considering the potential of ANP709 and the market opportunity.

Investment Strategies for the Anthem Biosciences IPO

Navigating an IPO requires a well-defined strategy. here’s a breakdown of potential approaches for investors considering ANTM:

1. Pre-IPO Access (Limited Availability):

Accessing shares before the IPO is typically reserved for institutional investors and high-net-worth individuals through their brokerage firms.

This offers the potential for immediate gains if the stock prices significantly upon listing.

Though, pre-IPO access is highly competitive and frequently enough requires substantial investment minimums.

2. IPO Day Trading:

Participate in the IPO through your brokerage account on the listing date.

Monitor the initial trading activity closely. Significant price swings are common in the first few hours.

Consider a short-term trading strategy, aiming to capitalize on initial momentum. Caution: IPO day trading is highly speculative.

3. Long-Term Investment:

If you believe in Anthem Biosciences’ long-term potential, consider purchasing shares after the initial IPO hype subsides.

focus on the company’s clinical trial progress, regulatory approvals, and commercialization efforts.

This strategy requires patience and a thorough understanding of the biopharmaceutical industry.

risk Factors to Consider Before Investing

Investing in IPOs, particularly in the biotech sector, carries inherent risks.Thorough due diligence is crucial.

Clinical Trial Risk: Phase 3 trials are critical. Failure to demonstrate efficacy or safety could significantly impact the stock price.

Regulatory Risk: Approval from the FDA is not guaranteed. Delays or rejection of ANP709 could negatively affect the company’s prospects.

competition: Other companies are developing therapies for SBS. Anthem Biosciences faces competition from established pharmaceutical firms.

*Financial Risk